research COVID-19: How Effective Are the Repurposed Drugs and Novel Agents in Treating the Infection?
Vaccination is the most effective way to reduce COVID-19 transmission.
Search
for
Sort by
Research
90-120 / 1000+ results 
research Productos naturales de origen vegetal contra el COVID-19
More clinical trials are needed to confirm if plant-based products can effectively treat COVID-19.
research Discovering the potential of natural remedies in the post COVID-19 complications based on in silico techniques
Natural compounds, especially Withaferin-A, may help treat post-COVID-19 complications, but some may have side effects.
research Assessment of Dermatological Disorders with Chronic Hepatitis C Virus Infection
People with chronic Hepatitis C often have skin problems like itching and contact dermatitis, especially older individuals and women.
research Cutaneous manifestations of COVID-19
Some skin symptoms, like chilblain-like lesions, can help identify COVID-19 and show how the immune system is responding.
research SUMMARY OF CONTACT WITH DR. MARIK. PULMONARY MEDICINE AND CRITICAL CARE. EASTERN VIRGINIA MEDICAL SCHOOL - USA.
The described COVID-19 treatments seemed effective in influencing the disease's course, duration, and severity.
research Clinical dermatoscopical response of glycyrrhizinic acid 0.1% spray in treating external anogenital warts in HIV patients: a case series
Glycyrrhizinic acid spray showed limited effectiveness in treating anogenital warts in HIV patients with low CD4 levels.
research Encapsulación en ciclodextrinas de compuestos con actividad frente a la alopecia androgénica masculina.
Encapsulating hair loss drugs in cyclodextrins improves their solubility and reduces scalp irritation.
research Antiandrogens and Androgen Inhibitors
Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.
research Computational screening of repurposed drugs and natural products against SARS-Cov-2 main protease (Mpro) as potential COVID-19 therapies
Some existing drugs and natural products might work against COVID-19 by targeting the virus's main protease.
research Off-label Prescription and Challenges in Clinical Practice: An Abridged Review
The review suggests doctors should carefully weigh risks and benefits of off-label drug use, involve patients in decisions, and calls for better regulations and monitoring.
research Chemically Induced Hair Loss/Alopecia
Some chemicals and drugs can cause hair loss, which usually grows back after stopping the treatment.
research Alopecia and drugs
Some medications can cause hair loss, and it's important to track when the hair loss starts after taking a new medication.
research Reporting on Adverse Clinical Events
Monitoring for adverse effects in clinical treatments is crucial.
research The role of dutasteride in the treatment of benign prostatic obstruction and related conditions
Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.
research British Society for Dermatopathology: Summaries of Papers
Some skin conditions are associated with other serious diseases, and office microscopy may miss many fungal infections.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research The impact of SARS-CoV-2 and COVID-19 on male reproduction and men’s health
COVID-19 might affect male fertility, but more research is needed to understand the full impact.
research Hirsutism, postpartum telogen effluvium, and male pattern alopecia
Hormonal changes during and after pregnancy can cause hair growth changes and hair loss, with treatments available for some conditions.
research Osteosclerosis and periostal new bone formation during indinavir therapy
Indinavir, especially with vitamin A, may cause bone changes, but switching to nelfinavir can reduce these effects.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Antiretroviral nucleoside and nucleotide analogues and mitochondria
Some HIV treatments can harm mitochondria, potentially causing side effects like lactic acidosis and nerve damage.
research BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report
Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
research A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
Ritlecitinib was generally well tolerated in children with alopecia areata.
research ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
research Patient Considerations when Using Ritlecitinib for Alopecia Areata in Adolescents: Guidance for the Clinicians
Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.